Q-omics provides the consensus-scored ARL17A profile across patient tissues and cancer cell-line models. ARL17A expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, ARL17A is differentially expressed in 7, with the highest sampling consensus in THCA. Additionally, ARL17A RNA expression shows 18,634 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight HNSC, THCA, and UVM as cancer lineages where ARL17A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ARL17A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ARL17A survival associations across molecular data types. ARL17A RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ARL17A RNA expression–survival associations across cancer types. High ARL17A expression shows unfavorable associations in KICH and ACC, but favorable associations in HNSC, SKCM, UCS and READ. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for ARL17A RNA expression.
This table summarizes ARL17A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for ARL17A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ARL17A shows lower tumor expression in THCA and KICH and higher tumor expression in LIHC, CHOL, BLCA and KIRP. The THCA box plot shows higher ARL17A RNA expression in normal versus tumor tissue (log2 FC = −0.139, t-test p = .001).
This table shows molecular features associated with ARL17A in patient tissues and cancer cell lines. In patient samples, ARL17A shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, ARL17A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in LIVER and SKIN.
